Treatment of chronic hepatitis B

Minerva Gastroenterologica e Dietologica

Volumn 56, Issue 4, 2010, Pages 451-465

  Cornberg, M ^a   Jaroszewicz, J ^a   Manns, M P ^a   Wedemeyer, H ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Hepatitis B virus; Hepatitis B, chronic; Interferon alpha

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ENTECAVIR; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RITUXIMAB; TELBIVUDINE; TENOFOVIR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ABSENCE OF SIDE EFFECTS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; BONE DENSITY; CHRONIC HEPATITIS; COMPETITIVE INHIBITION; DECOMPENSATED LIVER CIRRHOSIS; DELTA AGENT HEPATITIS; DEPRESSION; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG INDICATION; DRUG SAFETY; FATIGUE; FLU LIKE SYNDROME; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; KIDNEY TUBULE DISORDER; LACTIC ACIDOSIS; LEUKOCYTE COUNT; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; LOW DRUG DOSE; MIXED INFECTION; MONOTHERAPY; PASSIVE IMMUNIZATION; PREGNANCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SEROCONVERSION; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; VERTICAL TRANSMISSION; VIREMIA; VIRUS REACTIVATION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON-ALPHA; LAMIVUDINE; NUCLEOSIDES; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME;

EID: 79952261954     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 2004;350:1118-29. (Pubitemid 38298992)
2. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology 2009;49(5 Suppl):S45-55.
3. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008;48:335-52.
4. Thompson A, Locarnini S, Visvanathan K. The natural history and the staging of chronic hepatitis B: time for reevaluation of the virus-host relationship based on molecular virology and immunopathogenesis considerations? Gastroenterology 2007;133:1031-5.
5. Cornberg M, Protzer U, Dollinger MM, Petersen J, Wedemeyer H, Berg T et al. The German guideline for the management of hepatitis B virus infection: short version. J Viral Hepat 2008;15(Suppl 1):1-21.
6. European Association For The Study Of The L. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-42.
7. Cornberg M, Protzer U, Dollinger MM, Petersen J, Wedemeyer H, Berg T et al. Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the German guidelines for the management of HBV infection. Z Gastroenterol 2007;45:1281-328.
8. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73. (Pubitemid 43042691)
9. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-86.
10. Liaw YF, Raptopoulou-Gigi M, Cheinquer H, Sarin SK, Tanwandee T, Leung N et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with evidence of hepatic decompensation. Hepatology 2009;50(S4):505A.
11. Brunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, Gorin JM et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002;36:263-70. (Pubitemid 34146434)
12. Hu KQ, Schiff ER, Kowdley KV, Min AD, Shiffman ML, Lee WM et al. Histologic evidence of active liver injury in chronic hepatitis B patients with normal range or minimally elevated alanine aminotransferase levels. J Clin Gastroenterol 2010;44:510-6.
13. Park JY, Park YN, Kim DY, Paik YH, Lee KS, Moon BS et al. High prevalence of significant histology in asymptomatic chronic hepatitis B patients with genotype C and high serum HBV DNA levels. J Viral Hepat 2008 [Epub ahead of print].
14. Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009;49(5 Suppl):S156-65.
15. Wursthorn K, Wedemeyer H, Manns MP. Managing HBV in patients with impaired immunity. Gut 2010;59:1430-45.
16. Buster EH, Schalm SW, Janssen HL. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues. Best Pract Res Clin Gastroenterol 2008;22:1093-108.
17. Buster EH, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009;137:2002-9.
18. Craxi A, Di Bona D, Camma C. Interferon-alpha for HBeAg-positive chronic hepatitis B. J Hepatol 2003;39(Suppl 1):S99-105.
19. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312-23.
20. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-7.
21. Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008;135:459-67.
22. van Nunen AB, Hansen BE, Suh DJ, Lohr HF, Chemello L, Fontaine H et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003;52:420-4.
23. Chan HL, Leung NW, Hui AY, Wong VW, Liew CT, Chim AM et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 2005;142:240-50. (Pubitemid 40216241)
24. Cooksley WG, Piratvisuth T, Lee SD, Mahachai V, Chao YC, Tanwandee T et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003;10:298-305. (Pubitemid 36801917)
25. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365:123-9. (Pubitemid 40091801)
26. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-95. (Pubitemid 41007823)
27. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351:1206-17. (Pubitemid 39296307)
28. Wiegand J, Hasenclever D, Tillmann HL. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence. Antivir Ther 2008;13:211-20. (Pubitemid 351535372)
29. Fried MW, Piratvisuth T, Lau GK, Marcellin P, Chow WC, Cooksley G et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008;47:428-34. (Pubitemid 351280710)
30. Brunetto MR. A new role for an old marker, HBsAg. J Hepatol 2010;52:475-7.
31. Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009;49:1141-50.
32. Lau GK, Marcellin P, Brunetto M, Piratvisuth T, Kapprell HP, Button P et al. On-treatment HBsAg decline during peginterferon alpha-2a (40KD)+lamivudine in patients with HBeAg-positive CHB as a potential predictor of durable off-treatment response. Hepatology 2008;48:A910.
33. Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009;49:1151-7.
34. Rijckborst V, Hansen BE, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010;52:454-61.
35. Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010;52:1251-7.
36. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-2.
37. Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:422-30.
38. Schiff E, Simsek H, Lee WM, Chao YC, Sette H Jr, Janssen HL et al. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol 2008;103:2776-83.
39. Vigano M, Lampert P, Lavarone M, Tontini GE, Facchetti F, Colombo M. High risk of renal impairment and arterial hypertension during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B. Hepatology 2008;48:A897.
40. Fux CA, Rauch A, Simcock M, Bucher HC, Hirschel B, Opravil M et al. Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study. Antivir Ther 2008;13:1077-82.
41. Lange CM, Bojunga J, Hofmann WP, Wunder K, Mihm U, Zeuzem S et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009;50:2001-6.
42. Heathcote EJ, Marcellin P, Buti M, Gane E, de Man RA, Krastev Z et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis b. Gastroenterology 2010 [Epub ahead of print].
43. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-31.
44. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010;53:348-56.
45. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010;52:886-93.
46. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000;119:172-80.
47. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-22. (Pubitemid 37500436)
48. Marcellin P, Chang TT, Lim SG, Sieweret W, Tong M, Arterbrun S et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B (CHB) patients. Hepatology 2006;44:548A.
49. Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007;133:1437-44. (Pubitemid 350029745)
50. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL et al. Two-year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136:486-95.
51. Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005;129:528-36. (Pubitemid 41096641)
52. Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002;36:186-94. (Pubitemid 34700777)
53. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354 2006;10:1001-10. (Pubitemid 43357804)
54. Westland C, Delaney Wt, Yang H, Chen SS, Marcellin P, Hadziyannis S et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology 2003;125:107-16. (Pubitemid 36799112)
55. Dienstag JL, Cianciara J, Karayalcin S, Kowdley KV, Willems B, Plisek S et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003;37:748-55. (Pubitemid 36397384)
56. Lee KM, Cho SW, Kim SW, Kim HJ, Hahm KB, Kim JH. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J Viral Hepat 2002;9:208-12. (Pubitemid 36005519)
57. Reijnders JG, Perquin MJ, Zhang N, Hansen BE, Janssen HL. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology 2010;139:491-8.
58. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005;352:2673-81. (Pubitemid 41007822)
59. Fung SK, Wong F, Hussain M, Lok AS. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat 2004;11:432-8. (Pubitemid 39336224)
60. Wursthorn K, Jung M, Riva A, Goodman ZD, Lopez P, Bao W et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology (Published Online First: 12 October 2010. doi:10.1002/hep.23905), Published Online First: 12 October 2010. doi:10.1002/hep.23905.
61. Locarnini S, Hatzakis A, Heathcote J, Keeffe EB, Liang TJ, Mutimer D et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 2004;9:679-93. (Pubitemid 39434331)
62. Hashimoto Y, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H et al. Clinical and virological effects of long-term (over 5 years) lamivudine therapy. J Med Virol 2010;82:684-91.
63. Yuen MF, Seto WK, Chow DH, Tsui K, Wong DK, Ngai VW et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 2007;12:1295-303.
64. Cornberg M, Manns MP. [Entecavir - options and obstacles of an effective treatment for chronic hepatitis B]. Dtsch Med Wochenschr 2010;135:32-7.
65. Nguyen MH, Keeffe EB. Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides. J Viral Hepat 2009;16:149-55.
66. Zeuzem S, Gane E, Liaw YF, Lim SG, DiBisceglie A, Buti M et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol 2009;51:11-20.
67. Sung JJ, Lai JY, Zeuzem S, Chow WC, Heathcote EJ, Perrillo RP et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 2008;48:728-35.
68. Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007;133:1445-51.
69. van Bommel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010;51:73-80.
70. Reijnders JG, Deterding K, Petersen J, Zoulim F, Santantonio T, Buti M et al. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol 2010;52:493-500.
71. Kamili S, Sozzi V, Thompson G, Campbell K, Walker CM, Locarnini S et al. Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model. Hepatology 2009;49:1483-91.
72. Takkenberg B, Zaaijer HL, Weegink C, Terpstra V, Dijkgraaf MG, Jansen P et al. HBsAg level at baseline predicts HBsAg loss in chronic hepatitis B patients with combination therapy peginterferon alfa-2a and adefovir. Hepatology 2008;48:LB14.
73. Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006;44:675-84. (Pubitemid 44433724)
74. Moucari R, Boyer N, Ripault MP, Castelnau C, Mackiewicz V, Dauvergne A et al. Sequential therapy with adefovir dipivoxil and pegylated Interferon Alfa-2a for HBeAg-negative patients. J Viral Hepat 2010 [Epub ahead of print].
75. Sarin SK, Kumar M, Kumar R, Kazim SN, Guptan RC, Sakhuja P et al. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients. Am J Gastroenterol 2005;100:2463-71.
76. Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000;46:562-8.
77. Brown RS, Buti M, Goodwin D, Zhang S, Fagan EA. Hepatitis B virus (HBV) drugs in pregnancy: findings from the antiretroviral pregnancy registry. J Hepatol 2009;50:S4.
78. Terrault NA, Jacobson IM. Treating chronic hepatitis B infection in patients who are pregnant or are undergoing immunosuppressive chemotherapy. Semin Liver Dis 2007;27(Suppl 1):18-24. (Pubitemid 47301761)
79. del Canho R, Grosheide PM, Mazel JA, Heijtink RA, Hop WC et al. Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: protective efficacy and long-term immunogenicity. Vaccine 1997;15:1624-30.
80. Su GG, Pan KH, Zhao NF, Fang SH, Yang DH, Zhou Y. Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy. World J Gastroenterol 2004;10.910-2.
81. van Zonneveld M, van Nunen AB, Niesters HG, de Man RA, Schalm SW, Janssen HL. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 10(4): 294-7, 2003. (Pubitemid 36801916)
82. Xu WM, Cut YT, Wang L, Yang H, Liang ZQ, Li XM et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat 2009;16:94-103.
83. ter Borg MJ, Leemans WF, de Man RA, Janssen HL. Exacerbation of chronic hepatitis B infection after delivery. J Viral Hepat 2008;15:37-41.
84. Stange MA, Tutarel O, Pischke S, Schneider A, Strassburg CP, Becker T et al. Fulminant hepatic failure due to chemotherapy-induced hepatitis B reactivation: role of Rituximab. Zeitschrift Fur Gastroenterologie 2010;48:258-63.
85. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991;100:182-8.
86. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, Csako G. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008;148:519-28. (Pubitemid 351665421)
87. Yeo W, Zee B, Zhong S, Chan PK, Wong WL, Ho WM et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004;90:1306-11. (Pubitemid 38586252)
88. Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Forne M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004;53:1363-5. (Pubitemid 39120128)
89. Jang JW, Choi JY, Bae SH, Yoon SK, Chang UI, Kim CW et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 2006;43:233-40.
90. Katz LH, Fraser A, Gafter-Gvili A, Leibovici L, Tur-Kaspa R. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepat 2008;15:89-102.
91. Lau GK, He ML, Fong DY, Bartholomeusz A, Au WY, Lie AK et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 2002;36:702-9. (Pubitemid 34977182)
92. Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003;125:1742-9. (Pubitemid 37500439)
93. Rizzetto M, Bonino F, Verme G. Hepatitis delta virus infection of the liver: progress in virology, pathobiology, and diagnosis. Semin Liver Dis 1988;8:350-6. (Pubitemid 19045633)
94. Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol 2010;7:31-40.
95. Wedemeyer H, Heidrich B, Manns MP. Hepatitis D virus infection - not a vanishing disease in Europe! Hepatology 2007;45:1331-2; author reply 1332-3.
96. Serrano BC, Heidrich B, Jaroszewicz J, Deterding K, Raupach R, Cornberg M et al. Long-term outcome of hepatitis delta: a 14-year single center experience. Hepatology 2009;50:737A-7A.
97. Mederacke I, Bremer B, Heidrich B, Kirschner J, Deterding K, Bock T et al. Establishment of a novel quantitative hepatitis D virus (HDV) RNA assay using the Cobas TaqMan platform to study HDV RNA kinetics. J Clin Microbiol 2010;48:2022-9.
98. Wedemeyer H, Yurdaydin C, Dalekos G, Erhardt A, Cakaloglu Y, Degertekin H et al. 72 week data of the HIDIT-1 trial: A multicenter randomised study comparing peginterferon alpha-2a plus adefovir vs. peginterferon alpha-2a plus placebo vs. adefovir in chronic delta hepatitis. Journal of Hepatology 2007;46:S4-S4.
99. Yurdaydin C, Bozkaya H, Onder FO, Senturk H, Karaaslan H, Akdogan M et al. Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon. J Viral Hepat 2008;15:314-21. (Pubitemid 351326903)
100. Flink HJ, Sprengers D, Hansen BE, van Zonneveld M, de Man RA, Schalm SW et al. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy. Gut 2005;54:1604-9. (Pubitemid 41531780)